Premature infants of low and extremely low birth weight represent a challenge for neonatal intensive care units and paediatricians. These neonates may be at increased risk of insulin resistance and diabetes perinatally and during childhood. During the first week of postnatal life, infants born prematurely are at risk of abnormalities in glucose homeostasis. Additionally, there are major differences in their glucose/insulin homeostasis compared with infants born at term. Preterm infants are at risk of hypoglycaemia, due to decreases in deposits of glycogen and fat that occur during the third trimester, and also to transient hyperinsulinaemia. Hyperglycaemia may also be observed in preterm infants during the perinatal period. These infants are unable to suppress glucose production within a large range of glucose and insulin concentrations, insulin secretory response is inappropriate, insulin processing is immature and there is an increased ratio of the glucose transporters Glut-1/Glut-2 in fetal tissues, which limits sensitivity and hepatocyte reaction to increments in glucose/insulin concentration during hyperglycaemia. In addition, increased concentrations of tumour necrosis factor α present in intrauterine growth retardation (IUGR) and induce insulin resistance. It has been proposed that the reduced insulin sensitivity may result from adaptation to an adverse in utero environment during a critical period of development. We have investigated postnatal insulin resistance in 60 children born with very low birth weight and either small for gestational age or at an appropriate size for gestational age. This study showed that IUGR, rather than low birth weight itself, was associated with increased fasting insulin levels. As poor fetal growth may be associated with the development of obesity, type 2 diabetes and the metabolic syndrome in later life, it is important that we continue to increase our understanding of the effects of IUGR on postnatal growth and metabolism.

Keywords:
Glucose, Insulin, Intrauterine growth retardation, Preterm, Small for gestational age
1.
Farrag HM, Nawrath LM, Healey JE, Dorcus EJ, Rapoza RE, Oh W, Cowett RM: Persistent glucose production and greater peripheral sensitivity to insulin in the neonate vs. the adult. Am J Physiol 1997;272:E86–E93.
2.
Rizza RA, Mandarino LJ, Gerich JE: Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol 1981;240:E630–E639.
3.
Battaglia FC, Thureen PJ: Nutrition of the fetus and premature infant. Nutrition 1997;13:903–906.
4.
Ng PC, Lam CW, Lee CH, Wong GW, Fok TF, Chan IH, Ma KC, Wong E: Leptin and metabolic hormones in preterm newborns. Arch Dis Child Fetal Neonatal Ed 2000;83:F198–F202.
5.
Levitsky LL, Fisher DE, Paton JB, Delannoy CW: Fasting plasma levels of glucose, acetoacetate, D-beta-hydroxybutyrate, glycerol, and lactate in the baboon infant: correlation with cerebral uptake of substrates and oxygen. Pediatr Res 1977;11:298–302.
6.
Simmons RA, Flozak AS, Ogata ES: Glucose regulates glut 1 function and expression in fetal rat lung and muscle in vitro. Endocrinology 1993;132:2312–2318.
7.
Hoe FM, Thornton PS, Wanner LA, Steinkrauss L, Simmons RA, Stanley CA: Clinical features and insulin regulation in infants with a syndrome of prolonged neonatal hyperinsulinsim. J Pediatr 2006;148:207–212.
8.
Leipala JA, Raivio KO, Sarnesto A, Panteleon A, Fellman V: Intrauterine growth restriction and postnatal steroid treatment effects on insulin sensitivity in preterm neonates. J Pediatr 2002;141:472–476.
9.
Gray IP, Cooper PA, Cory BJ, Toman M, Crowther NJ: The intrauterine environment is a strong determinant of glucose tolerance during the neonatal period, even in prematurity. J Clin Endocrinol Metab 2002;87:4252–4256.
10.
Soto N, Bazaes RA, Pena V, Salazar T, Avila A, Iniguez G, Ong KK, Dunger DB, Mericq MV: Insulin sensitivity and secretion are related to catch-up growth in small-for-gestational-age infants at age 1 year: results from a prospective cohort. J Clin Endocrinol Metab 2003;88:3645–3650.
11.
Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM: Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993;36:62–67.
12.
Bazaes RA, Alegria A, Pittaluga E, Avila A, Iniguez G, Mericq V: Determinants of insulin sensitivity and secretion in very-low-birth-weight children. J Clin Endocrinol Metab 2004;89:1267–1272.
13.
Fewtrell MS, Doherty C, Cole TJ, Stafford M, Hales CN, Lucas A: Effects of size at birth, gestational age and early growth in preterm infants on glucose and insulin concentrations at 9–12 years. Diabetologia 2000;43:714–717.
14.
Hofman PL, Regan F, Jackson WE, Jefferies C, Knight DB, Robinson EM, Cutfield WS: Premature birth and later insulin resistance. N Engl J Med 2004;351:2179–2186.
15.
Bavdekar A, Yajnik CS, Fall CH, Bapat S, Pandit AN, Deshpande V, Bhave S, Kellingray SD, Joglekar C: Insulin resistance syndrome in 8-year-old Indian children: small at birth, big at 8 years, or both? Diabetes 1999;48:2422–2429.
16.
Ong KK, Petry CJ, Emmett PM, Sandhu MS, Kiess W, Hales CN, Ness AR, Dunger DB: Insulin sensitivity and secretion in normal children related to size at birth, postnatal growth, and plasma insulin-like growth factor-I levels. Diabetologia 2004;47:1064–1070.
17.
Hokken-Koelega AC, De Ridder MA, Lemmen RJ, Den Hartog H, De Muinck Keizer-Schrama SM, Drop SL: Children born small for gestational age: do they catch up? Pediatr Res 1995;38:267–271.
18.
Ravelli GP, Stein ZA, Susser MW: Obesity in young men after famine exposure in utero and early infancy. N Engl J Med 1976;295:349–353.
19.
Gale CR, Martyn CN, Kellingray S, Eastell R, Cooper C: Intrauterine programming of adult body composition. J Clin Endocrinol Metab 2001;86:267–272.
20.
Crescenzo R, Samec S, Antic V, Rohner-Jeanrenaud F, Seydoux J, Montani JP, Dulloo AG: A role for suppressed thermogenesis favoring catch-up fat in the pathophysiology of catch-up growth. Diabetes 2003;52:1090–1097.
21.
Dulloo AG: Regulation of fat storage via suppressed thermogenesis: a thrifty phenotype that predisposes individuals with catch-up growth to insulin resistance and obesity. Horm Res 2006;65(suppl 3):90–97.
22.
Cettour-Rose P, Samec S, Russell AP, Summermatter S, Mainieri D, Carrillo-Theander C, Montani JP, Seydoux J, Rohner-Jeanrenaud F, Dulloo AG: Redistribution of glucose from skeletal muscle to adipose tissue during catch-up fat: a link between catch-up growth and later metabolic syndrome. Diabetes 2005;54:751–756.
23.
Cooke RJ, Rawlings DJ, McCormick K, Griffin IJ, Faulkner K, Wells JC, Smith JS, Robinson SJ: Body composition of preterm infants during infancy. Arch Dis Child Fetal Neonatal Ed 1999;80:F188–F191.
24.
Fonseca VM, Sichieri R, Moreira ME, Moura AS: Early postnatal growth in preterm infants and cord blood leptin. J Perinatol 2004;24:751–756.
25.
Bhargava SK, Sachdev HS, Fall CH, Osmond C, Lakshmy R, Barker DJ, Biswas SK, Ramji S, Prabhakaran D, Reddy KS: Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med 2004;350:865–875.
26.
Singhal A, Fewtrell M, Cole TJ, Lucas A: Low nutrient intake and early growth for later insulin resistance in adolescents born preterm. Lancet 2003;361:1089–1097.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.